Boehringer Ingelheim an

  • Boehringer Ingelheim and University of Dundee      achieve milestone in collaboration aimed at developing novel protein      degradation medicines

  • Results published in Nature Chemical Biology      showcase the use of the broadly applicable structure-based PROTAC design      approach to discover highly potent and selective drug candidates

  • The first PROTAC is made freely available via Boehringer      Ingelheim’s open innovation portal, opnMe

  • Structure-based PROTAC design promises to      accelerate the development of therapies against currently intractable      cancer drivers

INGELHEIM, Germany & DUNDEE, Scotland -- (BUSINESS WIRE) --

Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer causing proteins. This brings together the expertise of Professor Alessio Ciulli, one of the pioneers in the field of Proteolysis targeting chimeras (PROTACs), based in the School of Life Sciences at Dundee, with Boehringer Ingelheim’s pharmaceutical expertise and commitment to bring innovative medicines to patients with cancer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190611005444/en/

PROTACs represent a new class of drug candidates with the potential to tackle compelling cancer targets which have failed traditional medicinal chemistry approaches. They work by harnessing the cell’s natural disposal system (the ubiquitin-proteasome). Candidate disease-causing proteins are labelled as “expired” proteins which the proteasome then shreds.

“PROTACs are a disruptive therapeutic modality which are bringing previously deemed undruggable targets within reach. Our collaboration will continue to work to bring this new class of medicines to patients,” said Darryl B. McConnell, Ph.D., Senior Vice President and Research Site Head, Boehringer Ingelheim, Vienna, Austria. “The joint team is making rapid progress and have successfully reached the first collaboration milestone setting a solid basis for achieving our goals.”

Since the initiation of the collaboration in 2016 and a significant expansion in 2018, the application of PROTACs has grown dramatically. However, designing PROTACs remains challenging and largely empirical in nature, hindering faster progress in the field. The partners have thus developed a structure-based design approach as a solid basis to accelerate further development. In addition, to boost PROTAC research around the world, Boehringer Ingelheim has made the protein degrader compound MZ-1, developed at the University of Dundee, freely available through its opnMe portal in 2018. Further PROTAC molecules are considered for release on opnMe based on the success of this initiative.

The joint team has reported recent progress in a number of scientific publications, including most recently in the journal Nature Chemical Biology. This publication highlights their approach to use 3-dimensional pictures at atomic resolution to design highly potent and selective drug candidates. The new approach has yielded the first PROTAC which shreds SMARCA2, a protein that drives the tumors of more than 20,000 new patients with cancer each year and for which drug discovery approaches have otherwise been unsuccessful to date.

“Our joint publication is a leading example of translating the detailed understanding we are developing of how PROTACs work, to craft degrader molecules that effectively tackle previously ‘undruggable’ targets”, said Alessio Ciulli, Ph.D., Chair of Chemical and Structural Biology at the University of Dundee, and winner of the 2016 RSC Capps Green Zomaya Award for medicinal chemistry. “The expansion marks an important milestone in the development of our alliance. It enables the joint team to drive the next phase of degrading highly-prized cancer targets previously intractable via other approaches”

Boehringer Ingelheim is focusing on developing innovative new treatment approaches providing outstanding value for patients. To achieve this, the company is increasing its commitment to external innovation, and is working with top partners from academia and industry worldwide. A growing network of academic collaborations reflects the company’s focus on emerging science that could open new avenues leading to the breakthrough medications of the future.

Please click on the link for “Notes to Editors” and “References”:


相关推荐
新闻聚焦
猜你喜欢
热门推荐
  • 一只船教育最新消息让人兴奋,退费工作

      在我29岁的时候,我们发了产生报考消防工程师的想法,可能是当时的生活过得很艰辛,而在工作方面一直等不到领导的赏识......

    02-27    来源:阿里教育网

    分享
  • BOP 天堂鸟与大家逆境中冒险

      刚推出新歌《冒险岛》BOP天堂鸟早前于屯门一个篮球场及荃湾一个工作室拍摄MV,面对现时疫情问题他们表示担心,希望新歌......

    04-02    来源:文旅新闻网

    分享
  • 新沐教育最新消息:响应最新政策号召,

      今年毕业了,想考个教资,但是不知道怎么报名,自己也不会教资复习,所以想报个辅导机构来辅助我学习。通过同学的介绍......

    02-27    来源:网络

    分享
  • 践行新型智库建设精神 创建中国创新策划

      本网讯(通讯员 周乐玲) 2019年11月23日,在中国创意策划年会上,由《中国企业报》集团打造的中国策划行业的学术智库机构中国......

    02-02    来源:中华企业在线

    分享
  • 言成教育最新消息,平台为了保证退费工

      当今社会健康管理师可是一个非常热门的职业,有很多青年人都会趁自己有空闲的时间选择报考健康管理师的培训课程增加个......

    02-27    来源:阿里教育网

    分享
  • 学慧网最新消息:想办理退费,请一定要

      如今学慧网已经倒闭跑路了,所以在他家还有剩余学费的小伙伴们,一定要按照我所说的去办退费。 我在2022年7月份在京东上......

    02-27    来源:阿里教育网

    分享
  • 学霸君最新消息 2023年平台计划完成所有

      我家孩子在上高二时就受到了疫情的破坏,因为疫情到大力影响,学生只能在家上网课,可是通过一段时间在家的学习,孩子......

    02-27    来源:阿里教育网

    分享
  • 逸成教育最新消息:现在学费退费了,学

      逸成教育在互联网之上一直在说着,能够帮助我做好学历提升,可是当时我明确表示了自己没有那么多钱去学习,他们就开始......

    02-28    来源:阿里教育网

    分享
  • 兴为教育发布了退费的最新消息,学员们

      作为一个中年男人,平时的收入还没有一个保安的高,虽然我每天都很忙碌,但是也不知道具体忙的什么,钱也没有挣到,家......

    02-27    来源:阿里教育网

    分享
  • 学璐教育新一轮退费公告来了,退费工作

      我是一名全职宝妈,平时把所有的精力全部放在了孩子的身上,但是两个孩子的学习成绩都不怎么样,这让我非常失望,认为......

    02-27    来源:阿里教育网

    分享
返回列表
Ctrl+D 将本页面保存为书签,全面了解最新资讯,方便快捷。